Bisphosphonates in the management of Paget's disease, fibrous dysplasia of bone, and osteoporosis;Bisphosphonates et remodelage osseux: Efficacite dans la maladie de Paget, la dysplasie fibreuse et l'osteoporose

Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur

Volumn 84, Issue 8, 1998, Pages 743-751

  Chapurlat, R ^a   Meunier, P J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; BONE PAIN; BONE REMODELING; FEMUR FRACTURE; FIBROUS DYSPLASIA; FOREARM FRACTURE; HUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY; BONE REMODELING; CALCIUM; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; FRACTURES, BONE; HUMANS; OSTEITIS DEFORMANS; OSTEOLYSIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 0032467983     PISSN: 00351040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. ADAMI S, MIAN M, GATTI P et coll. : Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone, 1994, 15, 415-417.
2. ADAMSON BB, GALLACHER SJ, BYARS J, RALSTON SH, BOYLE IT, BOYCE BF : Mineralization defects with pamidronate therapy for Paget's disease. Lancet, 1993, 342, 1459-1460.
3. ALEXANDRE CM, CHAPUY MC, VIGNON E, EDOUARD C, JOHNSTON CC, MEUNIER PJ : Treatment of Paget's disease of bone with ethane-1 hydroxy 1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day). Clin Orthop, 1983, 174, 193-205.
4. ALTMAN RD, JOHNSTON CC, KHAIRI MRA, WELLMAN H, SERAFINI AN, SANKEY RR : Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med, 1973, 289, 1379-1384.
5. AXELROD DW, TEITELBAUM SL : Results of long-term cyclical etidronate therapy, bone histomorphometry and clinical correlates. J Bone Miner Res, 1994, Suppl 9, 136S.
6. BALENA R, TOOLAN BC, SHEA M et coll. The effects of two-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest, 1993, 92, 2577-2586.
7. BELL NH, AVERY S, JOHNSTON CC : Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Met, 1970, 31, 283-290.
8. BLACK DM, CUMMINGS SR, THOMSON D et coll. : Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures. Lancet, 1996, 348, 1535-1541.
9. BONE HG, KLEEREKOPER M : Paget's disease of bone. J Clin Endocrinol Met, 1992, 75, 1179-1182.
10. BRANTUS JF, MEUNIER PJ : Effects of intravenous etidronate and oral corticosteroids in fibrodysplasia ossificans progressiva. Clin Orthop, 1998, 346, 117-120.
11. CHAPURLAT RD, DELMAS PD, LIENS D, MEUNIER PJ : Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res, 1997, 12, 1746-1752.
12. CHAPURLAT RD, DELMAS PD, MEUNIER PJ : Extended follow-up of patients with fibrous dysplasia of bone treated with pamidronate. Bone, 1998, Suppl 12, S56.
13. CHARHON S, CHAPUY MC, VALENTIN-OPRAN A, MEUNIER PJ : Intravenous etidronate for spinal cord dysfunction due to Paget's disease. Lancet, 1982, 7, 391-392.
14. CHESNUT CH, MC LUNG MR, ENSRUD KE et coll : Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med, 1995, 99, 144-152.
15. Consensus Development Conference : Prophylaxis and treatment of osteoporosis. Am J Med, 1991, 90, 107-110.
16. CUMMINGS SR, BLACK DM, THOMPSON DE : Alendronate reduces the risk of vertebral fracture in women without preexisting vertebral fracture: results of the Fracture Intervention Trial. J Bone Miner Res, 1997, Suppl 12, S149.
17. DE GROEN PC, LUBBE DF, HIRSCH LJ et coll. : Esophagitis associated with the use of alendronate. N Engl J Med, 1996, 348, 1016-1021.
18. DELMAS PD, CHAPUY MC, VIGNON E et coll. : Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Met, 1982, 54, 837-844.
19. DELMAS PD, MEUNIER PJ : Treatment of Paget's disease of bone. N Engl J Med, 1997, 336, 558-566.
20. 2 M.D.P.) in Paget's disease of bone. Arthritis Rheum, 1980, 23, 1185-1192.
21. ENSRUD KE, BLACK DM, PALERMO L et coll. : Treatment with alendronate prevents fractures in women at highest risk. Arch Int Med, 1997, 157, 2617-2624.
22. FRIJLINK WB, BIJVOET OLM, TE VELDE J, HEYNEN G : Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD). Lancet, 1979, 1, 799-803.
23. HARRIS WH, DUDLEY HR, BARRY RJ : The natural history of fibrous dysplasia. J Bone J Surg, 1962, 44A, 207-233.
24. HEANEY RP, SAVILLE PD : Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther, 1976, 20, 593-604.
25. HOSKING D, CHILVERS CED, CHRISTIANSEN C et coll. : Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med, 1998, 338, 485-492.
26. LIBERMAN U, WEISS SR, BROLL J et coll. : Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 1995,333, 1437-1443.
27. LIENS D, DELMAS PD, MEUNIER PJ : Long-term effects of pamidronate in fibrous dysplasia. Lancet, 1994, 343, 953-954.
28. LONG A, LONGHLIN T, TOWERS RP, MC KENNA TJ : Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin; aetiological and therapeutic implications. Int J Med Sci, 1988, 157, 229-234.
29. LUFKIN EG, ARGUETA R, WHITAKER MD et coll. : Pamidronate: an unrecognised problem of gastrointestinal tolerability. Osteoporosis Int, 1994, 4, 320-322.
30. MC CUNE DJ, BRUCH H : Osteodystrophia fibrosa: report of a case in which the condition was combined with precocious puberty, pathological pigmentation of the skin, and hyperparathyroidism, with review of the literature. Am J Dis Child, 1937, 54, 806-848.
31. MC LUNG MR, TOU CK, GOLDSTEIN NH, PICOT C : Tiludronate therapy for paget's disease of bone. Bone, 1995, Suppl 17, 493S-496S.
32. MAUTALEN CA, GONZALEZ D, GHIRINGHELLI G : Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone, 1985, 6, 429-439.
33. MEUNIER PJ, CHAPUY MC, ALEXANDRE C et coll. : Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet, 1979, 2, 489-492.
34. MEUNIER PJ, COINDRE J, EDOUARD CM, ARLOT ME : Bone histomorphometry in Paget's disease: quantitative and dynamic analysis of pagetic and non pagetic bone tissue. Arthritis Rheum, 1980, 23, 1095-1103.
35. MEUNIER PJ, SALSON C, MATHIEU L, et coll. : Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop, 1987, 217, 37-44.
36. MEUNIER PJ, VIGNOT E : Therapeutic strategy in Paget's disease of bone. Bone, 1995, Suppl 17, 489S-492S.
37. MEUNIER PJ, CONFAVREUX E, TUPINON I, HARDOUIN C, DELMAS PD, BALENA R : Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double blind, placebo-controlled study and 1-year follow-up). J Clin Endoc Met, 1997, 82, 2784-2791.
38. MILLS BJ, FRAUSTO A, SINGER FR et coll. : Multinucleated cells formed in vitro from Paget's bone marrow express viral antigen. Bone, 1994, 15, 443-448.
39. PRITCHARD JE : Fibrous dysplasia of bone. Am J Med Sci, 1951, 22, 313-332.
40. REBEL A, MALKANI A, BASLE M : Anomalies nucléaires des ostéoclastes de la maladie osseuse de Paget. Nouv Presse Med, 1974, 3, 1299-1301.
41. RIGGS BL, MELTON LJ : Involutional osteoporosis. N Engl J Med, 1986, 314, 1676-1684.
42. ROUX C, GENNARI C, FARRERONS J et coll. : Comparative prospective, double blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of bone. Arthritis Rheum, 1995, 38, 851-858.
43. 2 M.D.P.) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Int, 1973, 11, 196-214.
44. SIRIS ES, CANFIELD RE, JACOBS TP, STODDART KE, SPECTOR PJ : Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. Met Bone Dis Relat Res, 1981, 3, 301-308.
45. STEPHENSON RB, LONDON MD, HANKIN FM, KAUFERT H : Fibrous dysplasia: an analysis of options for treatment. J Bone Joint Surg, 1987, 69A, 400-409.
46. STORM T, THAMSBORG G, STEINICH T et coll. : Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med, 1990, 322, 1265-1271.
47. THOMAS T, LAFAGE MH, ALEXANDRE C : Atypical osteomalacia after 2 years of etidronate intermittent cyclic administration in osteoporosis. J Rheumatol, 1995, 22, 11.
48. TOOLAN BC, SHEA M, MYERS ER et coll. : Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res, 1992, 7, 1399-1406.
49. VAN BEEK E, KOEKSTRA M, VAN DE RUIT M, LÖWIK C, PAPAPOULOS S : Structural requirements for bisphosphonates actions in vitro. J Bone Miner Res, 1994, 12, 1875-1882.
50. VEGA E, GONZALEZ D, GHIRINGHELLI G, MAUTALEN CA : Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease. J Bone Miner Res, 1987, 2, 267-271.
51. VELLENGA CJLR, PAUWELS EKJ, BIJVOET OLM, FRIJLINK WB, MULDER JD, HERMANS J : Untreated Paget's disease of bone studied by scintigraphy. Radiology, 1984, 153, 799-805.
52. WATTS NB, HARRIS ST, GENANT HK et coll. : Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med, 1990, 323, 73-79.
53. YATES AJP, PERCIVAL RC, GRAY RES et coll. : Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet, 1985, 1, 1474-1477.